Parkinson's Disease

Because of the side effects of levodopa use, people diagnosed with Parkinson’s often choose to delay treatment with levodopa and start with other approved therapies. Typically, the first step is to start with medications that mimic levodopa, like Pramipexole, or medications that help increase natural dopamine levels, like Rasagiline. This clinical trial (phase 3) will research whether combining those two therapies at lower doses will result in good therapeutic effect, with fewer side effects. A previous clinical trial (Phase IIb) of the combination therapy showed positive results.

If you would like to speak to someone regarding this trial first check to see if you are eligible below. If it seems that you are eligible to take part, you will be contacted by phone so we can ask you additional eligiblity questions, and you will be able to ask any additional questions you may have about this clinical trial.

White brain outline

Check eligibility?

Study details

Study details

Drug
P2B001, Pramipexole, Rasagiline, Mirapex ER

Phase
3

Number of participants
525

Duration
The study includes up to 7 visits to a study center during approximately 14 to 18 weeks.

Is a placebo being used?
No

Sponsored by:
Pharma Two B

Will the results of this trial be published?
Yes

Will patients be able to continue taking the medication after the trial?
No

Costs
During the trial the investigational drugs and all study procedures and tests will be provided to patient at no cost. There will be no additional cost for patient to participate in this research trial.

If you would like to speak to someone regarding this trial first check above to see if you are eligible. If it seems that you are eligible to take part, you will be contacted by phone so we can ask you additional eligiblity questions, and you will be able to ask any additional questions you may have about this clinical trial.